Genetics of prion diseases  by Lloyd, Sarah E et al.
Genetics of prion diseases
Sarah E Lloyd, Simon Mead and John Collinge
Available online at www.sciencedirect.comPrion diseases are transmissible, fatal neurodegenerative
diseases that include scrapie and bovine spongiform
encephalopathy (BSE) in animals and Creutzfeldt–Jakob
disease (CJD) in human. The prion protein gene (PRNP) is the
major genetic determinant of susceptibility, however, several
studies now suggest that other genes are also important. Two
recent genome wide association studies in human have
identified four new loci of interest: ZBTB38-RASA2 in UK CJD
cases and MTMR7 and NPAS2 in variant CJD. Complementary
studies in mouse have used complex crosses to identify new
modifiers such as Cpne8 and provided supporting evidence for
previously implicated genes (Rarb and Stmn2). Expression
profiling has identified new candidates, including Hspa13,
which reduces incubation time in a transgenic model.
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Introduction
Prion diseases or transmissible spongiform encephalopa-
thies are fatal neurodegenerative diseases characterised
by long incubation periods, accumulation of abnormal
prion protein (PrPSc), spongiosis, gliosis and neuronal loss
[1]. They include scrapie and bovine spongiform ence-
phalopathy (BSE) in animals and Creutzfeldt–Jakob dis-
ease (CJD) in human. Sporadic CJD typically presents in
late middle-old age as a rapidly progressive multifocal
cortical dementia with additional neurological features
including cerebellar ataxia, pyramidal and extrapyramidal
motor dysfunction, myoclonus and dysfunction of the
visuoperceptual system. Despite increasing ascertain-
ment, these remain rare conditions, with typical inci-
dences in the developed world of 1–2 cases/million/
year. Variant CJD (vCJD), resulting from the human
transmission of BSE mainly through dietary exposure,
has steadily declined in incidence in the UK since 2000,
with a total 176 cases [1,2]. Although the decline in vCJD
Open access under CC BY license.www.sciencedirect.com is most welcome, the prevalence of subclinical infection
indicated by anonymous surveys of appendiceal tissue,
remains a significant concern at around 1:2000 in the UK
(http://www.hpa.org.uk/hpr/archives/2012/
news3212.htm#bnrmlprn). Subclinically infected individ-
uals may never convert to clinical cases, however they
pose risks for iatrogenic transmission by blood or blood
product transfusion, by dentistry and surgery.
PrP is central to the disease process with its misfolded
form thought to be the principal component of the
infectious particle. Mutations in the prion protein gene
(PRNP) are causative for inherited prion diseases [3,4]
and a common polymorphism (M129V) has a significant
effect on susceptibility and phenotype [5,6].
In this review we highlight progress since 2010 in deter-
mining genetic susceptibility to prion diseases. The use
of human genome-wide association studies (GWAS) and
complementary mouse studies reinforce the key role of
PRNP and identify new genetic modifiers. We outline the
challenge of verifying the role of putative modifiers and
propose a way forward for gene identification and vali-
dation (Figure 1).
Human genetics
Recent work has focussed on the collection of large
patient cohorts for GWAS, which has necessarily been
an international collaborative endeavour given that
human prion diseases are rare. As a generality from
common diseases, genetic risk factors discovered by
GWAS have been modest in their effects (odds ratios
1–1.2) requiring sample sizes of several thousand to have
the statistical power required for unequivocal detection of
significant variants. Two collaborative groups are working
in prion disease GWAS. The UK MRC Prion Unit in
collaboration with the Universities of Munich, Gottingen
and Perth has conducted a GWAS of sporadic CJD,
variant CJD, iatrogenic CJD, inherited prion disease,
and kuru involving over 2000 samples [7,8]. A
Europe-wide collaboration led by Dutch and Spanish
investigators published a GWAS of vCJD involving 93
samples [9]. In these studies, the PRNP locus was
unequivocally and strongly associated with risk of prion
disease, driven by the known coding variation at PRNP
codon 129.
In the European vCJD GWAS two single nucleotide
polymorphisms (SNPs) (rs4921542 and rs7565981)
reached genome-wide significance after pooling discov-
ery and replication populations. Rs4921542
( p = 1.6  108) is an intronic variant in the myotubularinCurrent Opinion in Genetics & Development 2013, 23:345–351
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From modifier gene discovery to functional validation. Current strategies for prion disease susceptibility gene discovery include both human and
mouse studies. These include human GWAS case–control studies and complementary QTL and GWAS studies in advanced mouse crosses. GWAS
results can be displayed as a Manhattan plot as shown here with highly significant hits shown for PRNP SNPs. Expression profiling of key tissues for
example comparing short (blue) and long (red) incubation time mice has also revealed new pathways and candidates. Next generation sequencing of
patients can now be used to identify high risk alleles at novel genes to generate an allelic mutation series as shown here for PRNP. Options for
functional validation of candidate genes include both in vitro (scrapie cell assay) and in vivo approaches (mouse models). GWAS – genome-wide
association studies; CJD – Creutzfeldt–Jakob disease; QTL – quantitative trait loci; SNP – single nucleotide polymorphism.
Current Opinion in Genetics & Development 2013, 23:345–351 www.sciencedirect.com
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PrP mutations and polymorphisms. A schematic representation of full length human PrP is shown with the cleaved signal sequences shown in grey and
the octapeptide repeat region in pink. Disease associated mutations are shown in red and non-synonymous non-pathogenic genetic variants in green.
OPRD – octapeptide repeat deletion; OPRI – octapeptide repeat insertion.related protein 7 gene (MTMR7), which is specifically
expressed in the central nervous system and dephosphor-
ylates phosphatidylinositol 3-phosphate and inositol 1,3-
bisphosphate. Rs7565981 ( p = 4.2  108) is in an inter-
genic region upstream of the neuronal PAS (per-ARNT-
sim) domain-containing protein 2 gene (NPAS2), a regu-
latory gene belonging to a family of transcription factors.
In the UK-German sporadic CJD study, no non-PRNP
loci achieved genome-wide signficance. SNPs at the
ZBTB38-RASA2 locus were associated with CJD in the
UK (rs295301, p = 3.13  108) but these SNPs showed
no replication evidence of association in German sporadic
CJD or in kuru based tests. Overall, it is likely that the
PRNP locus contains the only strong risk factors which act
universally across human prion diseases. Whilst some
genome wide significant loci have been proposed in
vCJD, the low incidence of this condition means that
there is no way at present to generate unequivocal genetic
evidence at these loci. The collective data are most
consistent with the findings in other diseases, of strong
effects being the exception but many risk loci of modest
effects. In prion disease this will require large collabora-
tive GWAS in sCJD to provide definitive statistical evi-
dence of these weak effects.
The PRNP locus and inherited prion disease
Genetic research in human prion disease has not
been restricted to GWAS. In inherited prion disease,www.sciencedirect.com important information has accrued about which variants
are completely penetrant, partially penetrant or simply
benign polymorphisms (Figure 2). Several publications
originate from groups that routinely sequence PRNP
and include the distributions of inherited prion disease
and new mutations from the UK, China, Japan, US, the
Netherlands, and further lessons on how easily inher-
ited prion disease, particularly that caused by trunca-
tion mutation, can be mistaken for Alzheimer’s disease
[10,11–18]. Sequencing the CEPH Human Diversity
Panel and the Pakistani population showed that small
insertions in the octapeptide repeat region of PRNP are
probably not pathogenic as they are found in the
healthy population, albeit rarely [10,13,19]. Sequen-
cing of the healthy Korean population showed both the
M232R and V180I variants implying that these may not
be pathogenic mutations [11]. Finally, a study of the
rare four octapeptide repeat mutation showed that
penetrance of the clinical disease is determined by
the genotype at codon 129. When the mutation is
linked to codon 129 methionine and the non-mutant
allele is also 129 methionine, the disease appears to be
penetrant, whereas it is non-penetrant when the non-
mutant allele is 129 valine [20].
Mouse models of prion disease
Human genetic studies provide the most direct link
between susceptibility genes and patients, however,
these are limited in power and inference regardingCurrent Opinion in Genetics & Development 2013, 23:345–351
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degenerative diseases mice are naturally susceptible to
prion diseases thus providing an ideal model organism for
both gene discovery and hypothesis testing.
Previous mouse quantitative trait loci (QTL) mapping
studies using simple crosses have successfully identified
many loci linked to prion disease incubation time [21–25].
A new report has added to these data using recombinant
inbred lines [26]. Many regions are implicated although
only loci on Mmu11 are replicated between the exper-
imental models. Large regions of this chromosome have
also been implicated in previous studies [21–23]. The
main disadvantage of these studies is the limited resol-
ution resulting in linkage to very large regions that have
proved intractable for candidate gene identification. The
availability of advanced crosses such as heterogeneous
stocks (HS) of mice and the development of the new
Collaborative Cross provide 10–20 higher resolution
and are already providing realistic prospects for identify-
ing individual candidate genes [27–29].
Heterogeneous stock (HS) mice
The Northport HS was successfully used to fine map and
identify candidate genes on Mmu19 (Hectd2) and Mmu15
(Cpne8) [30,31]. For Mmu15, the region of linkage was
reduced to 3.6Mb from the previous report of 30Mb [24].
Haplotype analysis and genotyping representative SNPs
identified Cpne8 as the most promising candidate. The
role of Cpne8 in prion disease has not been established
but it may be implicated in PrP processing and targeting
as Cpne8 is a member of the copine family that are Ca2+
dependent phospholipid binding proteins thought to be
involved in membrane trafficking [32].
The identification of Cpne8 and Hectd2 highlight the value
of HS mice for linkage mapping but they can also be used
for association studies, although the existence of large
haplotype blocks precludes single gene resolution. This is
illustrated by a study to validate two candidates, RARB
(retinoic acid receptor beta) and STMN2 (Stathmin-like
2), originally identified as part of a vCJD GWAS [7,31].
Statistical analysis showed a modest association for Stmn2
but a highly significant association for the Rarb locus
[31]. Although individual loci have been screened using
the HS mice their full potential has not yet been
exploited. The advent of high density SNP arrays, similar
to those available for the human genome, means that
GWAS and copy number variation analysis is now
possible. Combined with the availability of genomic
sequence for the HS parental strains, this should make
candidate gene discovery and validation easier.
mRNA expression
The use of high density microarrays to look at differential
expression of mRNA transcripts during disease pro-
gression has identified hundreds of differentiallyCurrent Opinion in Genetics & Development 2013, 23:345–351 expressed genes and more importantly highlighted gene
networks associated with the key cellular processes
[33,34]. These studies provide a global view of disease
associated changes but are difficult to interpret and many
of the pathways may be secondary effects rather than key
drivers of the process. We have taken the alternative
approach of looking for differential expression between
inbred lines of mice with different incubation times. We
used uninfected mice and to enrich for relevant genes we
looked for a correlation between expression level and
incubation time across five lines of mice [35]. Five poten-
tial candidates were identified including Hspa13 (Stch), a
member of the Hsp70 family of ATPase heat shock
proteins. To functionally test Hspa13 we generated an
overexpressing transgenic mouse and following infection
with three different prion strains showed highly signifi-
cant reductions in incubation time. The precise function
of Hspa13 is unknown but it has an intra-organellar
localisation and is induced by Ca2+ release suggesting a
role in ER stress and the unfolded protein response
(UPR) [36]. It has also been associated with TRAIL-
induced apoptosis [37].
Links to other neurodegenerative diseases
Prion diseases and other neurodegenerative disorders
share many common features including familial disease
as well as sporadic, aggregation of misfolded protein and
neuronal loss. Indeed, there is now evidence that cell to
cell spread in these diseases occurs through a ‘prion-like’
mechanism of seeded protein polymerisation [38,39].
The similarities between these diseases had led to cau-
sative genes in one disease being tested for an effect in
prion disease. Hyperphosphorylated microtubule-associ-
ated protein Tau forms the neurofibrillary tangles associ-
ated with Alzheimer’s disease and frontotemporal
dementia and a-synuclein (SNCA) is found in the protein
deposits (Lewy bodies) seen in Parkinson’s disease (PD).
Mice deficient in Tau and SNCA have been challenged
with prions and in both cases no difference in incubation
time was seen [40,41]. Mutations in SNCA are associated
with familial PD and in contrast, mice expressing mutant
SNCA (A53T) show a reduction in incubation time [42].
Functional validation
High throughput technologies such as GWAS and expres-
sion profiling suggest many candidate genes but the key
challenge is to translate this to phenotypic relevance
(Table 1). Therefore, the goal is to develop an in vitro
screen for functional validation. This is being done using
neuroblastoma derived cell lines that are highly suscept-
ible to prion infection and are able to sustain chronic
infection. The scrapie cell assay (SCA) allows rapid
bioassay of prions by counting the numbers of individual
infected cells in a culture following serial splits after
exposure to an unknown prion isolate and then comparing
to standard curves and can be combined with RNAi
technology to knockdown gene expression eitherwww.sciencedirect.com
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Table 1
Genes implicated in prion disease
Gene or locus Source (human/mouse) Comment Reference
PRNP GWAS (H) Seen across all human prion diseases and in
mouse experimental transmissions.
[7,8,9]
RARB GWAS (H) vCJD and iCJD [7,31]
SNP association (M) HS mice
STMN2 GWAS (H) vCJD and kuru [7,31]
SNP association (M) HS mice
ZBTB38-RASA2 GWAS (H) Sporadic CJD (UK) [8]
MTMR7 GWAS (H) vCJD [9]
NPAS2 GWAS (H) vCJD [9]
HECTD2 QTL (M) vCJD and kuru [30]
SNP association (H) HS mice
Cpne8 QTL (M) HS mice [45]
Stch Expression profile and
transmission studies (M)
Inbred and transgenic lines [35]
SNP, single nucleotide polymorphism; vCJD, variant Creutzfeldt–Jakob disease; HS, heterogeneous stock; QTL, quantitative trait locus; GWAS,
genome wide association study.transiently or stably to investigate the effect if any on
prion propagation [35,43]. The assay can be automated
and used either in its full format or using chronically
infected cells to measure curing of infection when target
genes are manipulated. The SCA is prion strain selective
and cannot fully substitute for the disease process in brain
or the peripheral pathogenesis before neuroinvasion in
natural infections and so some important genes will not
report in this system. However, the assay should capture
genes involved in the fundamentals of cellular prion
infection, propagation and clearance thus providing triage
for prioritising candidate genes for future studies.
The gold standard for functional validation is to generate
a mouse model such as a transgenic, or knockout and look
for a perturbation of phenotype such as incubation time.
Generating mouse models can be time consuming and
expensive, however, rapidly expanding public reposi-
tories such as the International Mouse Knockout Con-
sortium (www.knockoutmouse.org) are generating null
alleles for all mouse genes in embryonic stem (ES) cell
lines which should considerably speed up the process.
Alternatives include the use of viral vectors for RNAi
delivery to targeted regions of the brain for which proof of
concept has already been provided with Prnp knockdown
[44].
Conclusions
There is no doubt that genes other than PRNP contribute
to prion disease susceptibility and considerable progress
has been made towards their identification, however, in
human it is becoming clearer that there may be many
common variants but these are of modest effect. It may be
possible to screen larger sets of sporadic CJD, however,
the technology is now available for exome or genome
sequencing to look for rare variants which may havewww.sciencedirect.com stronger effects. The mouse genetic data complements
the human and the use of GWAS in HS mice promises to
deliver more candidate genes. The challenge will be to
test these candidates either in vitro or in vivo. Function-
ally validated candidates may then be considered as
potential therapeutic targets.
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